Compare Abeona Therapeutics Inc (ABEO) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares Ultra Semiconductors — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while ProShares Ultra Semiconductors trades at $90.25. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ABEO | USD | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.45 | $113.53 |
52-Week Low | $4.17 | $40.97 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
USD stock trades at $93.67, up 3.46% in the past 24 hours, with technical indicators signaling a bullish trend. The stock shows strong momentum above key support levels, though the RSI_6 at 99.69 suggests overbought conditions. A dividend of $0.14 is scheduled for June 30, 2026. Recent news highlights corporate developments in financial services and technology sectors.
The outlook remains positive given bullish technical signals and corporate actions, but high RSI indicates potential near-term pullback risks. Investors should weigh the dividend yield against valuation concerns amid limited fundamental data availability. Market sentiment is mixed, with institutional interest balanced by overbought technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
